Promising Therapy for Parkinson’s Advances to Next Stage

GT-02287, a new drug being developed by GAIN Therapeutics, is showing early promise for treating Parkinson’s disease—especially for those with a mutation in the GBA1 gene, which affects the function of the enzyme GCase. This enzyme plays a key role in cellular health, and its dysfunction is linked to some forms of Parkinson’s. Early Trial Completes Ahead of Schedule The Phase Ib open-label trial enrolled 15–20 participants and finished three months earlier than expected. This early completion reflects growing confidence among clinicians in the drug’s safety and potential to help improve symptoms. While the trial was initially focused on people with GBA1 mutations, early signs suggest that GT-02287 may also benefit those with idiopathic Parkinson’s (Parkinson’s with no known genetic cause). What This Phase Is Testing In this early-phase trial, both patients and clinicians know they’re receiving the drug, which helps assess tolerability and collect early efficacy and biomarker data. However, researchers acknowledge that this design could introduce bias, so the results will guide—but not confirm—effectiveness. What’s Next: A Larger, Blinded Study A more rigorous Phase II trial is planned for early 2026 and will include 100–200 patients. This next phase will be double-blinded, meaning neither patients nor doctors will know who receives the drug or a placebo. This design helps ensure that any improvements seen are truly due to the treatment, not expectation or chance. A New Kind of Drug Discovery GT-02287 was discovered using GAIN’s Magellan AI platform, which helps identify novel drug targets in parts of proteins that were previously hard to treat. This approach opens new possibilities for treating complex diseases like Parkinson’s in smarter, more targeted ways. Looking Ahead Results from the Phase Ib study—including important biomarker data from cerebrospinal fluid—are expected in late 2025. These findings will guide the next steps, including how the Phase II trial is funded. GAIN is exploring both self-funding and strategic partnerships, depending on the strength of the upcoming data. Why It Matters For people living with Parkinson’s disease, especially those facing limited treatment options, therapies like GT-02287 offer cautious optimism. While it’s still early, this approach targets an underlying biological process that could lead to more precise and effective treatment—and potentially benefit a broader range of individuals beyond those with known genetic risk factors.